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Abstract
Background: Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious
bleeding. The objective of this study is to determine the relative risk of cardiovascular adverse events or
haemorrhages in patients with peripheral artery disease treated with cilostazol in comparison to pentoxifylline users.
Methods: Population-based cohort study including all individuals older than 40 who initiated cilostazol or pentoxifylline
during 2009–2011 in SIDIAP database. The two treatment groups were matched through propensity score (PS).
Results: Nine thousand one hundred twenty-nine patients met inclusion criteria and after PS matching, there were 2905
patients in each group. 76% of patients were men, with similar mean ages in both groups (68.8 for cilostazol and 69.4 for
pentoxifylline). There were no differences in bleeding, cerebrovascular and cardiovascular events between both groups.
Conclusions: Patients treated with cilostazol were different from those treated with pentoxifylline at baseline, so they
were matched through PS. We did not find differences between treatment groups in the incidence of bleeding or
cardiovascular and cerebrovascular events. Cilostazol should be used with precaution in elderly polymedicated patients.
Keywords: Cilostazol, Pentoxifylline, Peripheral artery disease, Primary healthcare, Electronic health records, Haemorrhage,
Arrhythmia, Cardiovascular events, Coronary artery disease
Background
Peripheral artery disease (PAD) prevalence and incidence
are both age-related. Its prevalence in population older
than 60 ranges between 8.6 to 24.2% in women and 5.5 to
24.7% in men [1, 2] and it increases progressively with
ageing population [1]. Population studies conducted in
Spain have found a prevalence of PAD between 3.7 and 7.
6% in general population [3, 4]. PAD causes an impair-
ment in quality of life, decrease in life expectancy and it is
an important predictor of morbidity and mortality [5, 6].
Many people with PAD do not have symptoms, but
when they occur, intermittent claudication (IC) is the
main symptom. Treatment for IC is a combination of
preventive measures such as modification of risk factors,
physical activity, treatment of symptoms and antiplatelet
therapy [7, 8]. Currently, there are two drugs authorized
for PAD treatment; pentoxifylline [9] and cilostazol [10].
Cilostazol was approved by European Medicines Agency
(EMA) in 2002 and in Spain in 2009 to improve walking
distances in patients with IC [10].
Cilostazol is a phosphodiesterase III inhibitor which
was first approved for the treatment of symptoms related
to IC. It is a potent platelet-aggregation inhibitor and
has arterial vasodilatory effects [11]. Cilostazol is contra-
indicated in patients with severe renal impairment,
moderate or severe hepatic impairment, and known pre-
disposition to bleeding and in patients with history of
ventricular tachycardia, ventricular fibrillation or multi-
focal ventricular ectopic beats, or prolongation of the
QTc interval. Cilostazol has been associated with a num-
ber of spontaneous reports of cardiovascular adverse
effects (myocardial infarction, angina, and arrhythmias)
and serious bleeding [10, 12]. Haemorrhagic events in
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elderly patients co-treated with antiplatelets were also
reported by the Centro Autonómico de Farmacovigilan-
cia de Cantabria [13].
The EMA evaluated the benefit/risk of cilostazol in a
referral and recommended changes in the summary of
product characteristics (SmPC), including extension of
contraindications to patients with unstable angina
pectoris, recent acute myocardial infarction (AMI), or
recent coronary intervention. EMA also highlighted
cautions and concerns over haemorrhagic and vascular
events [12, 14]. Healthcare professionals in Europe have
been advised to use cilostazol for IC only in patients
where other lifestyle modifications such as smoking
cessation and exercise have not provided adequate
improvement and to continue use only in those patients
who have shown clinically relevant benefit after 3 months
of therapy. Other cautions include avoiding cilostazol in
patients receiving two or more additional antiplatelet or
anticoagulant agents and potentially avoiding use or
decreasing the dose in patients concomitantly receiving
strong inhibitors of CYP3A4 or CYP2C19 [12].
Cilostazol is recommended by guidelines as an effective
therapy in improving symptoms and increasing walking
distance in patients with lower extremity PAD [15, 16].
Nevertheless, the effect of cilostazol on morbidity and
mortality has not been fully determined. In this
population-based primary healthcare (PHC) cohort study,
we assess the safety of cilostazol for the treatment of PAD
patients in terms of incidence of cardiovascular events,
arrhythmias and haemorrhages during the follow-up.
The main objective of the study was to calculate the
relative risk of cardiovascular adverse events or bleeding
in patients with PAD treated with cilostazol in compari-
son to pentoxifylline users. The specific objectives were:
1) to calculate risks for cilostazol users versus pentoxifyl-
line users of: ischemic or coronary artery disease (CAD),
arrhythmias or haemorrhages; 2) to determine whether
the coexistence of type 2 diabetes mellitus (DM) may
increase adverse events of cilostazol; and 3) to determine
whether concomitant use of antiplatelet agents with
cilostazol increases the risk of bleeding.
Methods
Design
This is a population-based retrospective observational
cohort study.
Population
The study population were all individuals older than
40 years with a new prescription of cilostazol or pentoxi-
fylline between 2009 and 2011, from 274 PHC teams
from the Catalan Health Institute (Institut Català de la
Salut, ICS), which is the main health provider in
Catalonia, with a reference population of 5,835,000
patients (80% of the Catalan population).
We excluded patients with less than two visits to the
PHC centre during the year before the inclusion and pa-
tients with only one dispensing of the drugs of interest
during the study period.
All patients were followed-up from the cohort entry
date up to 31st December 2013, death or lost to follow-
up.
Data source
The main data source is SIDIAP (Information System
for Research in Primary Care), [17] which contains
anonymized clinical information of all PHC centres of
ICS. This information emerges from ECAP™, electronic
health records in PHC of the ICS, and it includes socio-
demographic characteristics, health conditions registered
as ICD10 codes, clinical parameters, toxic habits, labora-
tory data, and General Practitioners’ prescriptions with
their corresponding pharmacy invoice data. SIDIAP may
be linked with CMBD-HA (“minimum set of data at
hospital discharge”), [18] which contains diagnoses
coded with ICD9 at hospital discharge from all hospitals
in Catalonia, to obtain the data for comorbidities and for
the endpoints of the study.
Variables collected at baseline
The following variables were collected from SIDIAP
database: socio-demographic characteristics, smoking
status, body mass index (BMI, kg/m2), laboratory data
(total cholesterol and LDL-cholesterol determinations,
creatinine and estimated glomerular filtration calculated
by MDRD), blood pressure (BP) determinations, ankle-
brachial pressure index (ABPI) measures, diagnosis of
PAD, and other comorbidities of interest (hypertension,
type 2 DM, dyslipidemia). The following variables were
extracted from SIDIAP and CMBD-HA: previous history
of haemorrhages (total and specific gastrointestinal and
cerebral haemorrhages), stroke, CAD, and arrhythmias.
Exposure to drugs of interest (cilostazol and pentoxi-
fylline) and to comedications (diuretics, β-blockers,
calcium channel antagonists, angiotensin converter
enzyme inhibitors (ACEI), angiotensin receptor blockers
(ARB), nitrates and other vasodilators, lipid-modifying
agents, antidiabetic drugs and insulins, proton pump in-
hibitors, non-steroidal anti-inflammatory drugs (NSAID)
, oral anticoagulants (OAC), and antiplatelets) were
obtained from the pharmacy invoice registry, which
contains all information on pharmaceutical products
dispensed by community pharmacies with ICS prescrip-
tions, by ATC codes. All diagnosis codes as ICD9 and/or
ICD10 and ATC drug codes may be found at
(Additional file 1: Table S1).
Real et al. BMC Cardiovascular Disorders  (2018) 18:85 Page 2 of 7
Table 1 Baseline characteristics of the population included before (n = 9129) and after (n = 5810) propensity score matching:
socio-demographics, comorbidities, laboratory determinations, comedications
Variables Before PS-matching After PS-matching
N (%) Cilostazol (n = 3345) Pentoxifylline (n = 5784) p-value Cilostazol (n = 2905) Pentoxifylline (n = 2905) p-value
Gender
Women 711(21.3) 2444 (42.3) 0.001 695 (23.9) 676 (23.3) 0.557
Men 2634 (78.7) 3340 (57.7) 2210 (76.1) 2229 (76.7)
Mean age (SD) 68.5 (11.3) 70.1 (13.4) 0.001 68.8 (11.4) 69.4 (12.2) 0.058
PAD coded 1394 (41.7) 968 (16.7) 0.001 985 (33.9) 918 (31.6) 0.061
ABPI
< 0.7 195 (5.8) 214 (3.7) 0.001 156 (5.4) 146 (5.0) 0.359
≥ 0.7 151 (4.5) 248 (4.3) 132 (4.5) 154 (5.3)
Missing 2999 (89.7) 5322 (92.0) 2617 (90.1) 2605 (89.7)
Smoking status
Non-smoker 1037 (31.0) 2666 (46.1) 0.001 955 (32.9) 1102 (37.9) < 0.001
Smoker 1057 (31.6) 1085 (18.8) 869 (29.9) 725 (25.0)
Ex-smoker 944 (28.2) 1157 (20.0) 792 (27.3) 760 (26.2)
Missing 307 (9.2) 876 (15.1) 289 (9.9) 318 (10.9)
BMI, kg/m2, mean (SD) 28.3 (4.3) 28.7 (5.0) 0.017 28.4 (4.4) 28.5 (4.7) 0.505
< 25 295 (8.8) 482 (8.3) 0.001 253 (8.7) 271 (9.3)
25–30 712 (21.3) 913 (15.8) 603 (20.8) 538 (18.5)
> 30 438 (13.1) 789 (13.6) 382 (13.1) 419 (14.4)
Missing 1900 (56.8) 3600 (62.2) 1667 (57.4) 1677 (57.7)
Hypertension 2059 (61.6) 3396 (58.7) 0.008 1794 (61.8) 1811 (62.3) 0.646
Type 2 DM 1296 (38.7) 1876 (32.4) 0.001 1112 (38.3) 1120 (38.6) 0.829
Dyslipidemia 1531 (45.8) 2227 (38.5) 0.001 1271 (43.8) 1285 (44.2) 0.711
CAD 533 (15.9) 803 (13.9) 0.008 461 (15.9) 461 (15.9) 1
AF 152 (4.5) 457 (7.9) 0.001 145 (5.0) 177 (6.1) 0.067
Other arrhythmias 20 (0.6) 39 (0.7) 0.661 15 (0.5) 23 (0.8) 0.193
Prior stroke 313 (9.4) 506 (8.7) 0.327 268 (9.2) 286 (9.8) 0.421
Cerebral haemorrhage 10 (0.3) 24 (0.4) 0.381 10 (0.3) 6 (0.2) 0.317
Digestive haemorrhage 63 (1.9) 123 (2.1) 0.428 31 (1.1) 25 (0.9) 0.420
Other haemorrhages 81 (2.5) 160 (4.2) 0.323 75 (2.6) 74 (2.5) 0.934
BP
Bad control (≥140/90 mmHg) 1117 (33.4) 1605 (27.7) 0.001 954 (32.8) 880 (30.3) 0.041
Systolic BP, mean (SD) 137.9 (15.6) 135.9 (15.3) 0.001 137.9 (15.6) 136.2 (14.9) < 0.001
Diastolic BP, mean (SD) 74.7 (9.3) 74.5 (8.9) 0.347 74.7 (9.3) 74.5 (9.0) 0.405
Total
cholesterol, mg/dL, mean (SD) 193.3 (42.2) 194.8 (41.5) 0.269 194.0 (42.1) 193.6 (42.8) 0.801
LDL cholesterol, mg/dL, mean (SD) 116.8 (36.4) 117.8 (35.4) 0.440 117.3 (36.4) 115.9 (35.8) 0.346
≤ 100 479 (34.3) 688 (31.8) 0.119 401 (33.9) 407 (34.4) 0.068
> 100 916 (65.7) 1474 (68.2) 783 (66.1) 777 (65.6)
≤ 150 1135 (81.4) 1764 (81.6) 0.864 960 (81.1) 979 (82.7) 0.311
> 150 260 (18.6) 398 (18.4) 224 (18.9) 205 (17.3)
eGFR (MDRD), mL/min/1.73m2
≤ 30 30 (0.9) 83 (1.4) 0.001 27 (0.9) 31 (1.1) 0.728
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Outcomes of interest
We collected the following events from CMBD-HA dur-
ing the study period: haemorrhages (total and specific
gastrointestinal and cerebral haemorrhages), stroke,
CAD, and arrhythmias.
Sample, matching process, and statistical power
The two cohorts were matched in order to balance
socio-demographic characteristics, comorbidity and
comedications. The method used was the “Nearest
Neighbour”, which is based on Propensity Score (PS)
Link logit with “MatchIt” library from R (v3.0.1).
The variables used to build this PS were: sex, age,
BMI, smoking status, comorbidities, BP control, esti-
mated glomerular filtration as per MDRD, ABPI and co-
medications at baseline.
The final matched sample included 5810 individuals,
2905 per group. After the matching process, a 36.4%
of the sample (n = 3319) was removed and the poten-
tial bias between the two samples (overall vs
matched) was reduced in an 83%. Assuming that a
cohort of 5810 patients with a 5-years follow-up
period had an incidence of a cardiovascular event of
4.3% in one of the groups (incidence data of symp-
tomatic patients from ARTPER study [3]), and
between 1% (HR = 1.23) to 2% (HR = 1.46) of events
attributable to cilostazol, the statistical power would
be 53–96%. This approximation has been carried out
with a Log-Rank test with an alpha-level of 5% in a
bilateral contrast.
Statistical analysis
Descriptive statistics were used to summarize overall
information. In order to compare the baseline character-
istics between the treatment groups, Chi-square test was
used for categorical variables and Student’s t-test for
quantitative variables.
Conditional Cox regression models were used to
estimate incidence rates and hazard ratios (HR) and the
person/time value was used as offset. Risk functions and
HR were estimated with their 95% confidence intervals
(CI) to compare the two groups. 95% CI and p-values
were calculated by robust standard errors (by clusters).
Goodness of fit and proportional hazards assumption of
Cox models were assessed through Schoenfeld residuals
method.
These analyses were conducted in the population
of 5810 patients and in three subgroups of patients:
> 65 years-old, patients diagnosed with type 2 DM
and those co-treated with antiplatelet agents.
All statistical tests were two-sided at the 5% significance
level. The analyses were performed using SPSS-IBM PC
v.18 and Stata v.11 (Stata Corp., Collage Station, TX).
Table 1 Baseline characteristics of the population included before (n = 9129) and after (n = 5810) propensity score matching:
socio-demographics, comorbidities, laboratory determinations, comedications (Continued)
Variables Before PS-matching After PS-matching
N (%) Cilostazol (n = 3345) Pentoxifylline (n = 5784) p-value Cilostazol (n = 2905) Pentoxifylline (n = 2905) p-value
30–59 387(11.6) 754 (13.0) 352 (12.1) 374 (12.9)
≥ 60 1222 (36.5) 1854 (32.1) 1021 (35.1) 1027 (35.4)
Missing 1706 (51.0) 3093 (53.5) 1505 (51.8) 1473 (50.7)
Diuretics 863 (25.8) 1905 (32.9) < 0.001 796 (27.4) 813 (28.0) 0.618
β-blockers 625 (18.7) 1082 (18.7) 0.979 560 (19.3) 546 (18.8) 0.640
Calcium channel antagonists 721 (21.6) 1216 (21.0) 0.550 639 (22.0) 635 (21.9) 0.899
ACEI* 1288 (38.5) 1931 (33.4) 0.001 1102 (37.9) 1092 (37.6) 0.787
ARB* 949 (28.4) 1444 (25.0) 0.001 833 (28.7) 857 (29.5) 0.488
Vasodilators 397 (11.9) 779 (13.5) 0.028 360 (12.4) 372 (12.8) 0.635
Lipid modifying agents 2077 (62.1) 2652 (45.9) 0.001 1716 (59.1) 1698 (58.5) 0.631
Antidiabetic drugs and insulins 1275 (38.1) 1793 (31.0) < 0.001 1104 (38.0) 1079 (37.1) 0.498
Proton pump inhibitors 1967 (58.8) 3541 (61.2) 0.023 1724 (59.3) 1759 (60.6) 0.349
NSAID* 1233 (36.9) 2290 (39.6) 0.010 1085 (37.3) 1094 (37.7) 0.807
OAC* 342 (10.2) 696 (12.0) 0.009 301 (10.4) 311 (10.7) 0.669
Antiplatelets 2169 (64.8) 2740 (47.4) 0.001 1797 (61.9) 1776 (61.1) 0.571
* PS propensity score, SD standard deviation, PAD peripheral artery disease, ABPI ankle-brachial pressure index, BMI body mass index, DM diabetes mellitus,
CAD coronary artery disease, AF atrial fibrillation, BP blood pressure, eGFR estimated glomerular filtrate rate, MDRD modification of diet in renal disease formula,
ACEI angiotensin-converter enzyme inhibitors, ARB angiotensin-receptor blockers, NSAID non-steroidal anti-inflammatory drugs, OAC oral anticoagulants
** ABPI, mean value in the last 6 months. BP, mean values in the last year. Cholesterol measures, last value in prior 6 months. eGFR, mean value in the last 6 months.
Co-medications, 6 months prior to inclusion
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Results
During the study period, 9129 patients met the inclusion
criteria; 3345 were receiving treatment with cilostazol
and 5784 with pentoxifylline. Patients in the two groups
were different in most baseline characteristics (Table 1).
After PS matching, there were 2905 patients per
group. As shown in Table 1, most patients (76%) in both
cohorts were men. Their mean ages were similar in both
groups. There were differences between groups in the
frequency of smokers; more than 25% of patients in both
groups were current smokers. The percentages of miss-
ing values of this variable were 9.9 and 10.9% in cilosta-
zol and pentoxifylline users, respectively.
We analysed the frequency and incidence of bleeding,
cerebrovascular and cardiovascular events comparing
the two cohorts (Table 2). There were no statistically
significant differences between them for the overall
population included.
We also conducted three subgroup analyses for the
following groups of patients: 1) older than 65, 2) patients
with type 2 DM, and 3) patients co-treated with antipla-
telets. We did not find significant differences between
the two groups of treatment in the subgroup of people
older than 65 or in the patients with type 2 DM. For
patients co-treated with antiplatelets, we found differ-
ences between cilostazol and pentoxifylline in the rates
of other haemorrhages, which include eye bleeding,
haemorrhages of the anus and rectum, epistaxis and
haemorrhages not elsewhere classified; and in the rates
of any haemorrhage. The incidence of these events was
higher in pentoxifylline users than in cilostazol users
(Table 3).
Table 2 Frequency and incidence of events in the study
population (n = 5180)
Risk at 5 years
Outcomes N (%) CI95% HR CI95% p valuea
Gastrointestinal haemorrhage
Cilostazol 35 1.2 0.8–1.6 1.10 0.7–1.8 0.711
Pentoxifylline 31 1.1 0.7–1.4
Cerebral haemorrhage
Cilostazol 23 0.8 0.5–1.1 0.79 0.5–1.4 0.392
Pentoxifylline 30 1.0 0.7–1.4
Other haemorrhages
Cilostazol 92 3.2 2.5–3.8 0.83 0.6–1.2 0.267
Pentoxifylline 115 4.0 3.2–4.7
Any haemorrhage
Cilostazol 115 4.0 3.2–4.7 0.82 0.6–1.1 0.119
Pentoxifylline 143 4.9 4.1–5.7
CAD
Cilostazol 287 9.9 8.8–11.0 0.94 0.8–1.1 0.433
Pentoxifylline 305 10.5 9.4–11.6
Stroke
Cilostazol 161 5.5 4.7–6.4 0.94 0.8–1.2 0.564
Pentoxifylline 171 5.9 5.0–6.7
AF
Cilostazol 194 6.7 5.8–7.6 1.02 0.8–1.2 0.857
Pentoxifylline 190 6.5 5.6–7.4
Other arrhythmias
Cilostazol 89 3.1 2.4–3.7 1.14 0.8–1.5 0.392
Pentoxifylline 78 2.7 2.1–3.3
CI 95% Confidence Interval with 95%, HR hazard ratio, CAD coronary artery disease,
AF atrial fibrillation
ap-value computed using univariate Cox regression with robust standard errors
by clusters (pairs)
Significant p-values are in boldface
Table 3 Frequency and incidence of events in the population
with co-treatment with antiplatelets (n = 3573)
Risk at 5 years
Outcomes N (%) CI95% HR CI95% p valuea
Gastrointestinal haemorrhage
Cilostazol 15 0.8 0.4–1.3 0.67 0.3–1.3 0.232
Pentoxifylline 22 1.2 0.7–1.8
Cerebral haemorrhage
Cilostazol 14 0.8 0.4–1.2 1.23 0.6–2.7 0.604
Pentoxifylline 13 0.7 0.3–1.1
Other haemorrhages
Cilostazol 55 3.1 2.3–3.9 0.65 0.5–0.9 0.014
Pentoxifylline 85 4.8 3.8–5.8
Any haemorrhage
Cilostazol 69 3.8 3.0–4.7 0.72 0.5–1.0 0.040
Pentoxifylline 98 5.5 4.5–6.6
CAD
Cilostazol 224 12.5 10.9–14.0 0.93 0.8–1.1 0.427
Pentoxifylline 237 13.3 11.8–14.9
Stroke
Cilostazol 103 5.7 4.7–6.8 0.83 0.6–1.1 0.180
Pentoxifylline 121 6.8 5.6–8.0
AF
Cilostazol 122 6.8 5.6–8.0 1.0 0.8–1.3 0.999
Pentoxifylline 120 6.8 5.6–7.9
Other arrhythmias
Cilostazol 61 3.4 2.6–4.2 1.42 1.0–2.1 0.082
Pentoxifylline 42 2.4 1.7–3.1
CI 95% Confidence Interval with 95%, HR hazard ratio, CAD coronary artery disease,
AF atrial fibrillation
ap-value computed using univariate Cox regression with robust standard errors
by clusters (pairs)
Significant p-values in boldface
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Discussion
In this cohort study of the safety of cilostazol in PAD,
we identified 9129 patients who initiated cilostazol or
pentoxifylline during the study period. They differed in
most of socio-demographic and clinical characteristics.
After PS matching, the cohort was composed by 2905
cilostazol users and 2905 pentoxifylline users with com-
parable characteristics between groups.
We analysed the frequency and incidence of bleeding,
cerebrovascular and cardiovascular events and we found
non-statistically significant differences between cilostazol
and pentoxifylline. We also conducted three sub-analyses
in the following subgroups of patients: 1) population ≥
65 years-old, 2) patients diagnosed with type 2 DM and 3)
patients co-treated with antiplatelet agents. For patients
co-treated with other antiplatelets, pentoxifylline showed
higher incidences than cilostazol for overall haemorrhages,
and for the group of other haemorrhages, which includes
eye bleeding, haemorrhages of the anus and rectum, epi-
staxis and haemorrhages not elsewhere classified.
Our results are in line with previous studies, which
did not find increases in haemorrhages, CAD or
arrhythmic events in cilostazol-treated patients. In the
clinical trial conducted by Dawson et al. [19] patients
were randomized to receive cilostazol, pentoxifylline or
placebo and the maximal walking distance was measured
after 4, 8, 12, 16, 20 and 24 weeks. They also studied the
frequency of common side effects and the group of
“serious adverse events” had similar frequencies in the
three groups, with non-significant differences.
In a systematic review of clinical trials comparing cilos-
tazol with placebo or other drugs currently known to in-
crease walking distance, such as pentoxifylline, 3718
patients were assessed and there was no clear evidence of
a difference between any of the treatment groups and risk
of AMI, stroke or all-cause mortality [20].
In the cohort study conducted by Leeper et al. [21], 232
patients with PAD treated with cilostazol were matched by
1:5 PS with 1160 patients not taking this drug. Over a mean
follow-up of 4.2 years, they did not find association between
cilostazol and cerebrovascular or cardiovascular events (OR
for stroke 1.13, 95%CI 0.82–1.55; OR for AMI 1.00, 95%CI
0.71–1.39) or death (OR 0.86, 95%CI 0.63–1.18). They did
not find increase in arrhythmic events either.
Previous published data in Spain [13] studied elderly pa-
tients with underlying comorbidities and receiving a con-
siderable number of concomitant medications. The small
sample size of the study does not allow establishing definite
conclusions. Cilostazol should be used for IC only in pa-
tients with no contraindications for the treatment and
should be used cautiously in elderly polymedicated pa-
tients, in those receiving two or more additional antiplate-
let or anticoagulant agents and in those receiving strong
inhibitors of CYP3A4 or CYP2C19.
Strengths and limitations
The strengths of our study are the use of an automated
health data which implies large number of patients
included, representativeness for the general population,
complete socio-demographic and health records, long
follow-up, and real clinical practice data.
Some limitations of observational studies conducted
with electronic health records are missing or incomplete
information, prescriptions not linked with diagnoses
coded and possible confounders. Specific limitations of
our study are the possibly incomplete information on
outcomes, as we only captured data of haemorrhages,
CAD events or arrhythmias from the hospital discharges
(CMBD-HA) and not from the records in PHC from
SIDIAP. This may result in an infraestimation of events
which could be related to cilostazol treatment. However,
this would produce an infraestimation in both cohorts.
Another limitation is the relatively low number of
patients with PAD diagnosis coded during the study
period, because ABPI determination was not imple-
mented in all PHC centres in our setting. Nowadays, this
problem is solved.
Conclusion
Patients treated with cilostazol were clearly different
from those treated with pentoxifylline at baseline, so
they were matched through PS.
After matching, we did not find differences between
treatment groups in the incidence of bleeding or cardio-
vascular and cerebrovascular events. We did not find
differences in specific subgroups either, except an in-
crease in overall haemorrhages rates with pentoxifylline
in patients co-treated with additional antiplatelets.
Cilostazol should be used with precaution in elderly
polymedicated patients in order to avoid adverse events.
Additional file
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NSAID: Non-steroidal anti-inflammatory drugs; OAC: Oral anticoagulants;
OR: Odds ratio; PAD: Peripheral artery disease; PHC: Primary healthcare;
PS: Propensity score; SIDIAP: Information system for research in primary care;
SmPC: Summary of product characteristics
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